Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.
The plasma GH response to GHRH (100 micrograms i.v.) was evaluated either alone or after pretreatment with pyridostigmine (120 mg orally 1 h prior to GHRH) in 9 younger men (age range: 22-39 years) and in 9 healthy elderly men (age range: 63-77 years). On a different occasion, subjects were tested with pyridostigmine alone. Basal concentrations of glucose, cortisol, androgens, estrogens, thyroid hormones and GH were similar in all subjects, whereas insulin-like growth factor was lower in elderly men. The GH response to GHRH was significantly lower in the older (mean peak was 6 times higher than baseline) than in the younger group (mean peak was 11.3 times higher than baseline). The pretreatment with pyridostigmine induced a striking increase in the GH response to GHRH in the younger subjects (mean peak was 26 times higher than baseline), whereas it produced only a slight increase in the GHRH-induced GH response in elderly men (mean peak was 8.7 times higher than baseline). When pyridostigmine was given alone, plasma GH levels rose significantly in both groups; however, the pyridostigmine-stimulated GH response was significantly higher in younger (mean peak was 6 times higher than baseline) than in older subjects (mean peak was 2.5 times higher than baseline). These data indicate that the cholinergic stimulatory regulation of GH release is reduced in elderly subjects. Since acetylcholine inhibits hypothalamic somatostatin release, the reduced cholinergic tone in elderly subjects may result in an increased somatostatinergic tone.
Division of Clinical Medicine, University of Parma School of Medicine, Italy.
V
V
Coiro
R
R
Volpi
P
P
Bertoni
G
G
Finzi
A
A
Marcato
A
A
Caiazza
R
R
Colla
G
G
Giacalone
G
G
Rossi
P
P
Chiodera
D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology; D004357:Drug Synergism; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000494:pharmacology*; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D013004:Somatostatin / Q000502:physiology
D011950:Receptors, Cholinergic; D013004:Somatostatin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D011729:Pyridostigmine Bromide